A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
Background The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. Case presentation We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic senso...
Uložené v:
| Vydané v: | Journal for immunotherapy of cancer Ročník 6; číslo 1; s. 110 - 6 |
|---|---|
| Hlavní autori: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
22.10.2018
BMJ Publishing Group LTD BMJ Publishing Group |
| Predmet: | |
| ISSN: | 2051-1426, 2051-1426 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown.
Case presentation
We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren’s syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement.
Conclusions
Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren’s syndrome induced by pembrolizumab treatment. |
|---|---|
| AbstractList | The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown.BACKGROUNDThe prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown.We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren's syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement.CASE PRESENTATIONWe report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren's syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement.Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren's syndrome induced by pembrolizumab treatment.CONCLUSIONSHerein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren's syndrome induced by pembrolizumab treatment. BackgroundThe prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown.Case presentationWe report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren’s syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement.ConclusionsHerein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren’s syndrome induced by pembrolizumab treatment. Background The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. Case presentation We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren’s syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement. Conclusions Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren’s syndrome induced by pembrolizumab treatment. The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren's syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement. Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren's syndrome induced by pembrolizumab treatment. Abstract Background The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. Case presentation We report the case of a melanoma patient treated for 8 months with pembrolizumab who developed a subacute ataxic sensory neuronopathy (SNN), including a right trigeminal neuropathy. Salivary gland biopsy showed inflammatory changes suggestive of Sjögren’s syndrome, while brain MRI revealed enhancement of the right trigeminal ganglia. A high level of protein and pleocytosis was found in the cerebrospinal fluid, with negative cultures. Nerve conduction studies revealed the absence of sensory nerve action potentials in the upper and lower limbs and reduced motor responses in the upper limbs, fulfilling criteria for SNN. Blood tests revealed an important inflammatory syndrome, hemolytic anemia, elevation of total IgG levels and the presence of ANA autoantibodies specific to anti-SSA (52 and 60 kd). All these elements were absent before the initiation of the treatment with pembrolizumab. Initially, there was a clinical response following intravenous frontline methylprednisone, but the subacute relapse required the introduction of second-line treatment with intravenous immunoglobulins and then rituximab, which led to a quick clinical improvement. Conclusions Herein, we describe the first case of a patient who developed a typical SNN as a complication of severe neuro-Sjögren’s syndrome induced by pembrolizumab treatment. |
| ArticleNumber | 110 |
| Author | Ghosn, Jaqueline Vicino, Alex Michielin, Olivier Kuntzer, Thierry Obeid, Michel Coukos, George |
| Author_xml | – sequence: 1 givenname: Jaqueline surname: Ghosn fullname: Ghosn, Jaqueline organization: Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV – sequence: 2 givenname: Alex surname: Vicino fullname: Vicino, Alex organization: Department of Neurology, Lausanne University Hospital CHUV – sequence: 3 givenname: Olivier surname: Michielin fullname: Michielin, Olivier organization: Department of Medical Oncology, Lausanne University Hospital CHUV – sequence: 4 givenname: George surname: Coukos fullname: Coukos, George organization: Department of Medical Oncology, Lausanne University Hospital CHUV, Ludwig Institute for Cancer Research – sequence: 5 givenname: Thierry surname: Kuntzer fullname: Kuntzer, Thierry organization: Department of Neurology, Lausanne University Hospital CHUV – sequence: 6 givenname: Michel surname: Obeid fullname: Obeid, Michel email: michel.obeid@chuv.ch organization: Department of Medicine, Division of Immunology and Allergy, Lausanne University Hospital CHUV, Vaccination and Immunotherapy Center, Lausanne University Hospital CHUV, Medical School Pitié-Salpêtrière, Sorbonne University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30348223$$D View this record in MEDLINE/PubMed https://hal.sorbonne-universite.fr/hal-01913644$$DView record in HAL |
| BookMark | eNp9UkFu1DAUjVARLaUHYIMisYFFwD92HHuDNKoKrTQSC2Bt2c7PNKPEHuxkpGHFNbgIF-AmnAQPaaEdCVb--n7v_fft9zg7ct5hlj0F8gpA8NeREVZWBQFRpEIW7EF2UpIKCmAlP7pTH2dnMa4JIUAoFUI8yo4poUyUJT3JLhZ5xC0GzK2OmPs2dzgFX3xY__i-Cuh-fv0W87hzTfAD5p1rJotNbnb5BgcTfN99mQZtnmQPW91HPLs5T7NPby8-nl8Wy_fvrs4Xy8JWNRkLjYICR6SatpWkWKJhjSUNEVSDNE1lgNJWGqPrFlBCbays2opbzVkreUtPs6tZt_F6rTahG3TYKa879bvhw0rpMHa2R5U2RahESYQGhmgFlVpXzGjGpWzBJK03s9ZmMgM2Ft0YdH9P9P6N667Vym8VB8lZTZLAy1ng-oB2uViqfY-ABMoZ20LCvrgZFvznCeOohi5a7Hvt0E9RlVDWPLmtWII-P4Cu_RRcelZVcioAKiJlQj276_7P_NufTYB6BtjgYwzYKtuNeuz8fpmuV0DUPkZqjlHyKtQ-RmpvAA6Yt-L_45QzJyasW2H4a_rfpF_woNmY |
| CitedBy_id | crossref_primary_10_1016_j_rdc_2024_01_003 crossref_primary_10_1097_WCO_0000000000000867 crossref_primary_10_1136_annrheumdis_2020_217139 crossref_primary_10_1212_WNL_0000000000011795 crossref_primary_10_5937_afmnai40_40566 crossref_primary_10_1186_s13046_023_02851_6 crossref_primary_10_1016_j_clim_2020_108497 crossref_primary_10_1038_s41571_019_0218_0 crossref_primary_10_1056_NEJMra2023935 crossref_primary_10_1007_s10072_022_05920_4 crossref_primary_10_1007_s40487_023_00224_9 crossref_primary_10_1634_theoncologist_2019_0467 crossref_primary_10_36290_far_2021_025 crossref_primary_10_1038_s41571_020_0400_4 crossref_primary_10_1038_s41571_020_0401_3 crossref_primary_10_1093_rheumatology_keab698 crossref_primary_10_1136_jitc_2020_001287 crossref_primary_10_2217_imt_2021_0071 crossref_primary_10_1016_j_annonc_2020_03_285 crossref_primary_10_1093_rheumatology_kez295 crossref_primary_10_1097_BOR_0000000000000935 crossref_primary_10_1016_j_annonc_2022_10_001 crossref_primary_10_1136_jitc_2020_000604 crossref_primary_10_1080_1744666X_2024_2370327 crossref_primary_10_1136_jnnp_2019_321663 crossref_primary_10_1111_1759_7714_13249 crossref_primary_10_1212_WNL_0000000000011340 crossref_primary_10_1007_s40278_018_54841_6 crossref_primary_10_1038_s41573_021_00259_5 crossref_primary_10_1186_s40425_018_0481_0 crossref_primary_10_3389_fimmu_2025_1586426 crossref_primary_10_1038_s41571_020_0352_8 |
| Cites_doi | 10.1200/JCO.2014.58.3377 10.1200/JCO.2014.57.4756 10.1097/CMR.0000000000000232 10.1186/s40425-017-0210-0 10.1136/annrheumdis-2016-210820 10.1056/NEJMra1703481 10.1056/NEJMoa1503093 10.1111/j.1529-8027.2012.00411.x 10.2147/OTT.S133699 10.1002/art.39859 10.1002/mus.20100 10.1186/s40425-017-0224-7 10.1093/brain/awh605 10.1093/brain/awp136 10.1001/jamaneurol.2017.1912 10.1093/annonc/mdw443 10.1136/jnnp.2005.081547 10.1016/j.jns.2015.12.044 10.1186/s40425-017-0300-z |
| ContentType | Journal Article |
| Copyright | The Author(s). 2018 2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Attribution |
| Copyright_xml | – notice: The Author(s). 2018 – notice: 2018 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/ ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Attribution |
| DBID | C6C AAYXX CITATION NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s40425-018-0429-4 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| EndPage | 6 |
| ExternalDocumentID | oai_doaj_org_article_388e158208a14eec839aa54ba4699f1b PMC6196470 oai:HAL:hal-01913644v1 30348223 10_1186_s40425_018_0429_4 |
| Genre | Journal Article |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ADBBV ADRAZ ADUKV AFKRA AHBYD AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS EJD FYUFA GROUPED_DOAJ H13 HMCUK HYE IAO IHR IHW INH INR ITC KQ8 M1P M48 M~E OK1 PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RMJ ROL RPM RSV SOJ UKHRP AAYXX AFFHD CITATION -A0 3V. ABDBF ACRMQ ADINQ ALIPV C24 NPM 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c570t-ae8316ee3a3f593e2eb4dc0d083a19bd5b133f9bba7f1e917bc95f56ca64f96f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 36 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000448184000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2051-1426 |
| IngestDate | Mon Nov 10 04:35:38 EST 2025 Tue Nov 04 01:46:55 EST 2025 Tue Oct 14 20:27:58 EDT 2025 Fri Sep 05 06:28:04 EDT 2025 Sat Nov 29 14:24:32 EST 2025 Thu Jan 02 22:59:58 EST 2025 Sat Nov 29 03:12:22 EST 2025 Tue Nov 18 21:51:57 EST 2025 Sat Sep 06 07:27:21 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Checkpoint inhibitors Pembrolizumab Immune-related adverse events Neuro-Sjögren’s syndrome PD-1 |
| Language | English |
| License | Attribution: http://creativecommons.org/licenses/by Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c570t-ae8316ee3a3f593e2eb4dc0d083a19bd5b133f9bba7f1e917bc95f56ca64f96f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Case Study-2 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 |
| OpenAccessLink | https://doaj.org/article/388e158208a14eec839aa54ba4699f1b |
| PMID | 30348223 |
| PQID | 2638115099 |
| PQPubID | 2040222 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_388e158208a14eec839aa54ba4699f1b pubmedcentral_primary_oai_pubmedcentral_nih_gov_6196470 hal_primary_oai_HAL_hal_01913644v1 proquest_miscellaneous_2127658254 proquest_journals_2638115099 pubmed_primary_30348223 crossref_citationtrail_10_1186_s40425_018_0429_4 crossref_primary_10_1186_s40425_018_0429_4 springer_journals_10_1186_s40425_018_0429_4 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-10-22 |
| PublicationDateYYYYMMDD | 2018-10-22 |
| PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-22 day: 22 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAbbrev | j. immunotherapy cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2018 |
| Publisher | BioMed Central BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BioMed Central – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | HE Teulings (429_CR12) 2015; 33 J King (429_CR14) 2017; 5 S Le Burel (429_CR16) 2018; 77 RC Graham (429_CR6) 2006; 77 BY Kong (429_CR13) 2016; 26 CH Shiboski (429_CR7) 2017; 69 AM Menzies (429_CR18) 2017; 28 Robert H.I. Andtbacka (429_CR4) 2015; 33 C Robert (429_CR3) 2015; 372 KJ Harrington (429_CR17) 2017; 10 JC Kao (429_CR2) 2017; 74 K Mori (429_CR11) 2005; 128 MA Postow (429_CR1) 2018; 378 JP Camdessanche (429_CR8) 2012; 17 T Kuntzer (429_CR9) 2004; 30 E Shiuan (429_CR15) 2017; 5 I Puzanov (429_CR19) 2017; 5 JP Camdessanche (429_CR5) 2009; 132 JC Antoine (429_CR10) 2016; 361 |
| References_xml | – volume: 33 start-page: 2780 issue: 25 year: 2015 ident: 429_CR4 publication-title: Journal of Clinical Oncology doi: 10.1200/JCO.2014.58.3377 – volume: 33 start-page: 773 issue: 7 year: 2015 ident: 429_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.4756 – volume: 26 start-page: 202 issue: 2 year: 2016 ident: 429_CR13 publication-title: Melanoma Res doi: 10.1097/CMR.0000000000000232 – volume: 5 start-page: 8 year: 2017 ident: 429_CR15 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0210-0 – volume: 77 start-page: 468 issue: 3 year: 2018 ident: 429_CR16 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210820 – volume: 378 start-page: 158 issue: 2 year: 2018 ident: 429_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra1703481 – volume: 372 start-page: 2521 issue: 26 year: 2015 ident: 429_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa1503093 – volume: 17 start-page: 331 issue: 3 year: 2012 ident: 429_CR8 publication-title: J Peripher Nerv Syst doi: 10.1111/j.1529-8027.2012.00411.x – volume: 10 start-page: 3867 year: 2017 ident: 429_CR17 publication-title: Onco Targets Ther doi: 10.2147/OTT.S133699 – volume: 69 start-page: 35 issue: 1 year: 2017 ident: 429_CR7 publication-title: Arthritis Rheumatol doi: 10.1002/art.39859 – volume: 30 start-page: 255 issue: 3 year: 2004 ident: 429_CR9 publication-title: Muscle Nerve doi: 10.1002/mus.20100 – volume: 5 start-page: 19 year: 2017 ident: 429_CR14 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0224-7 – volume: 128 start-page: 2518 issue: Pt 11 year: 2005 ident: 429_CR11 publication-title: Brain doi: 10.1093/brain/awh605 – volume: 132 start-page: 1723 issue: Pt 7 year: 2009 ident: 429_CR5 publication-title: Brain doi: 10.1093/brain/awp136 – volume: 74 start-page: 1216 issue: 10 year: 2017 ident: 429_CR2 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2017.1912 – volume: 28 start-page: 368 issue: 2 year: 2017 ident: 429_CR18 publication-title: Ann Oncol doi: 10.1093/annonc/mdw443 – volume: 77 start-page: 973 issue: 8 year: 2006 ident: 429_CR6 publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp.2005.081547 – volume: 361 start-page: 187 year: 2016 ident: 429_CR10 publication-title: J Neurol Sci doi: 10.1016/j.jns.2015.12.044 – volume: 5 start-page: 95 issue: 1 year: 2017 ident: 429_CR19 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0300-z |
| SSID | ssj0001033888 |
| Score | 2.3061635 |
| Snippet | Background
The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is... The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is unknown. We... BackgroundThe prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is... The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing autoimmunity is... Abstract Background The prevalence of connective tissue disease (CTD) induced by immune checkpoint inhibitors (CPIs) in the absence of pre-existing... |
| SourceID | doaj pubmedcentral hal proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 110 |
| SubjectTerms | Antibodies Biopsy Case Report Case Reports Checkpoint inhibitors Exocrine glands Hemoglobin Hepatitis Immune-related adverse events Immunology Immunotherapy Life Sciences Medicine Medicine & Public Health Melanoma Metastasis Monoclonal antibodies Neuro-Sjögren’s syndrome Oncology PD-1 Pembrolizumab Remission (Medicine) Targeted cancer therapy Viruses |
| SummonAdditionalLinks | – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3bbtNAEB1BihAv3C-GggziCbSK116vvU8ooFZFolUkQCpPq72MaRF1Qi6V4Inf4Ef4Af6EL2HW2SQKFX3i1btObM_ZmTOe9RmApxSyuWukZNaKnAmDgimPnhG58IVXYajumk1UBwf14aEaxs-jp3Fb5dIndo56ofYc9m2TE-77kQtvzPs5wSZwGaVejL-w0EMq1FpjQ42LsBWEt-oebA1f7w8_rN-5ZJSQ1XUsbvJa9qcigJby6ZoFz8zERnjqVPwp6ByFPZJnCejZfZR_FVO7GLV77f_e3XW4GrlqOliA6wZcwPYmXN6P1fhbsDNIKa7iBFNHsTAdNWmnjsnefvr1k9L49vf3H9N0KYmQUvJPMPKp_ZqO8cSGbkHf5ifG3ob3uzvvXu2x2JaBubLKZsxgXXCJWJiiKVWBOVrhXeaJzBmurC8t5b2NstZUDUdKB61TZVNKZ6RolGyKO9BrRy3eg1Q55TMn0VirhM8zm1cekUsfvqgtC5FAtrSGdlGzPLTO-Ky73KWWemFATQbUwYCaTnm2OmW8EOw4b_LLYOLVxKC13R0YTT7quHQ1QQZ5SUypNlwgOqKUxpTCGiGVarhN4AkBZOM39gZvdDhG_JkXxDhPeQLbS8Pr6CWmem3nBB6vhml9h6KNaXE0pzk8r4glEqATuLuA2-qviH4IInhFAtUGEDeuZXOkPT7qNMRlEGKrsgSeLyG7vqx_Pq7759_EA7iSh5VEkT3Pt6E3m8zxIVxyp7Pj6eRRXIx_AOoWRBc priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELagINQL_9BAQQZxAlnEiePYxwW16gEqRAH1ZvlnQotottrsVoITr8GL8AK8CU_C2JtsFQpIcI3txJl84_kmY88Q8ghNNveNlMw5UTBhQTAdIDAkF6EMOjapVGyi3t1V-_v6VX-Ouxt2uw8hybRSJ7VW8mknIr7Q9VUsLqJMnCcX0NqpqI2v996d_ljJ0etSqo9g_nbkyAalVP1oWQ7iRsizLPPsZslfIqbJEG1f-a9XuEou97yTTpZAuUbOQXudXHrZR9ZvkK0JRRsJM6Ae7RqdNjRlumR7H75_Q5e8_fHla0eH9AYUHXmERKDuEz2GIxcr_3xeHFl3k7zd3nrzfIf1JRaYr-p8ziyokkuA0pZNpUsowIng84DEzHLtQuXQh220c7ZuOKBr57yumkp6K0WjZVPeImvttIUNQrXXIfcSrHNahCJ3RR0AuAzxdGxViozkg9CN7_OPxzIYH03yQ5Q0S_EYFI-J4jE45PFqyPEy-cbfOj-LX3LVMebNThems_emV0ODyABeIetRlgsAj_TQ2ko4K6TWDXcZeYg4GN1jZ_LCxGvIhXmJ7PGEZ2RzgInpNb4zBS5kkV1rnZEHq2bU1RiAsS1MF9iHFzUyPvTJM3J7iarVo5BKCCRrZUbqEd5Gcxm3tIcHKR-4jEnV6jwjTwbUnU7rj-K680-975L1IsIWjXZRbJK1-WwB98hFfzI_7Gb3kwL-BMxfLJs priority: 102 providerName: Springer Nature |
| Title | A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab |
| URI | https://link.springer.com/article/10.1186/s40425-018-0429-4 https://www.ncbi.nlm.nih.gov/pubmed/30348223 https://www.proquest.com/docview/2638115099 https://www.proquest.com/docview/2127658254 https://hal.sorbonne-universite.fr/hal-01913644 https://pubmed.ncbi.nlm.nih.gov/PMC6196470 https://doaj.org/article/388e158208a14eec839aa54ba4699f1b |
| Volume | 6 |
| WOSCitedRecordID | wos000448184000002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RBZ dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: 7X7 dateStart: 20130501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: BENPR dateStart: 20130501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2051-1426 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: PIMPY dateStart: 20130501 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 2051-1426 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0001033888 issn: 2051-1426 databaseCode: RSV dateStart: 20131201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwEB5BQagXxD8pZRUQJ1DUOHEc-7hFWxWJrlYtoOVk-WeiFtFstT-V4MRr8CK8AG_CkzBOskuXCrhwiZTYSazx2PN9sfMNwDMK2cxVQiTW8izhBnmiPPqEwIXPvQpFskk2UQ6HcjxWowupvsKesFYeuDXcTi4lsoLilDSMIzoK6MYU3BridapiNsy-hHoukKnm60pK1EvKbhmTSbEz48E9iTnLJMzBCV8LRI1eP4WX47Ab8jLUvLxj8rdl0yYa7d2Cmx2MjPtt82_DFazvwI2DbqH8Lgz6MYU8nGLsKEzFkypuhCuTow_fvxHDrn98-TqLl2oFMfFy6mEf20_xGZ7akMjn8-LU2Hvwdm_w5uV-0mVMSFxRpvPEoMyZQMxNXhUqxwwt9y71hLMMU9YXlihppaw1ZcWQmJp1qqgK4YzglRJVfh826kmNDyFWTvnUCTTWKu6z1GalR2TCh59di5xHkC7Np10nJx6yWnzUDa2QQrcW12RxHSyu6Zbnq1vOWi2Nv1XeDX2yqhhksJsL5By6cw79L-eI4Cn16Noz9vuvdbhG0JblBAbPWQTbyw7X3QCe6YzmpQCWlYrgyaqYhl5YTzE1ThZUh2UlATii2BE8aP1j9SpCBpywVx5BueY5a21ZL6lPjht5bxE00so0ghdLH_vVrD-aa-t_mOsRbGZhgFBozrJt2JhPF_gYrrvz-cls2oOr5bhsjrIH13YHw9Fhrxl1dDZ6dTB6T2eHR-9-AggPLwQ |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELZKQcCF_59AgYDgUhQ1dhwnPiC0QKutul0hUaS9Gf9M2kU0u-xPUTnxGrwER16AN-FJGGeTXS0VvfXANbYTJ_lm5ht7PEPIUzTZ1BZCRMZwFnENPJIOXITkwiVO-qa8KjaRdbt5ryffrpAfzVkYH1bZ6MRKUbuB9WvkGwyB4tmLlC-HnyNfNcrvrjYlNGaw2IHjL-iyjV9sv8H_-4yxrc291-2orioQ2TSLJ5GGPKECINFJkcoEGBjubOyQi2gqjUsNum2FNEZnBQX0ZoyVaZEKqwUvpCgSvO85ch71eOZDyLJetljTidHhy_N685TmYmPMvVCgv55HXvNHfMn8VVUC0Kgd-BjMkwT3ZJzmX5u1lQ3cuvq_fb1r5ErNtsPWTDyukxUob5CLu3U8wU2y2QqRGcAIQovWPBwUYZXfM3r38dfP_RGUv799H4dNUoewXzoUBBea43AIh8bXO_o6PdTmFnl_Ji9xm6yWgxLuklBa6WIrQBsjuWOxYZkDoML5M8FpwgMSN_9b2Trrui_-8UlV3lcu1AwiCiGiPEQUDlmfDxnOUo6c1vmVB9G8o88WXl0YjPZVrXwUghJoilwv15QDWCTFWqfcaC6kLKgJyBOE4NI92q2O8tfQA6AJcuYjGpC1Blqq1nNjtcBVQB7Pm1FD-W0nXcJgin0oy5DnshQne2cG6PmjkEBxpKhJQLIlqC_NZbml7B9UWdCFTyWXxQF53gjFYlr__Fz3Tn-JR-RSe2-3ozrb3Z375DLzcos8hbE1sjoZTeEBuWCPJv3x6GEl-CH5cNay8gf_zZaY |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQRUX3o9AgYDgAoo2dhwnPiC00K5atawqAdLeXD8m7SKaXfZRVE78Df4IB678E34J42yyq6Witx64xnbiJN_MfGOPZwh5iiab2kKIyBjOIq6BR9KBi5BcuMRJ35RXxSaybjfv9eTeCvnZnIXxYZWNTqwUtRtYv0beYggUz16kbBV1WMTeRufV8HPkK0j5ndamnMYMIjtw8gXdt_HL7Q38188Y62y-f7MV1RUGIptm8STSkCdUACQ6KVKZAAPDnY0d8hJNpXGpQReukMborKCAno2xMi1SYbXghRRFgve9QC5mSZL5shFZL1us78To_OV5vZFKc9Eacy8g6LvnkbcCEV8yhVXFADRwhz4e8zTZPR2z-dfGbWUPO1f_5y95jVypWXjYnonNdbIC5Q2y9raOM7hJNtshMgYYQWjRyoeDIqzyfkbvPv76cTCC8ve37-OwSfYQ9kuHAuJCcxIO4cj4Okhfp0fa3CIfzuUlbpPVclDCXRJKK11sBWhjJHcsNixzAFQ4f1Y4TXhA4ubfK1tnY_dFQT6pyivLhZrBRSFclIeLwiHP50OGs1QkZ3V-7QE17-iziFcXBqMDVSslhQAFmiIHzDXlABbJstYpN5oLKQtqAvIE4bh0j632rvLX0DOgCXLpYxqQ9QZmqtZ_Y7XAWEAez5tRc_ntKF3CYIp9KMuQ_7IUJ3tnBu75o5BYcaSuSUCyJdgvzWW5pewfVtnRhU8xl8UBedEIyGJa__xc985-iUdkDUVE7W53d-6Ty8yLMNIXxtbJ6mQ0hQfkkj2e9Mejh5UOCMn-eYvKH5OQn0w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+severe+case+of+neuro-Sj%C3%B6gren%E2%80%99s+syndrome+induced+by+pembrolizumab&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Ghosn%2C+Jaqueline&rft.au=Vicino%2C+Alex&rft.au=Michielin%2C+Olivier&rft.au=Coukos%2C+George&rft.date=2018-10-22&rft.pub=BMJ+Publishing+Group&rft.issn=2051-1426&rft.eissn=2051-1426&rft.volume=6&rft_id=info:doi/10.1186%2Fs40425-018-0429-4&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=oai%3AHAL%3Ahal-01913644v1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |